NCT04996121招募中1 期
The Safety Tolerability Pharmacokinetic Characteristics and Efficacy of XZP-5955 Tablets in Patients With NTRK or ROS1 Gene Fusion Locally Advanced or Metastatic Solid Tumors in a Single-arm Open-label Multi-center Phase I/II Clinical Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 360
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose (MTD) (Phase I dose escalation)
研究概览
简要总结
A phase I/II study to examine the safety, tolerability, pharmacokinetics and efficacy of XZP-5955 tablets in patients with advanced solid tumors harboring NTRK or ROS1 gene fusion
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects aged ≥18 years old;
- •Phase I dose escalation period: Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor, assessed by investigator that no standard therapy exists, or the tumor has relapsed, progressed or was nonresponsive to available therapies, or intolerance, or not suitable to standard therapy at current stage. Priority will be given to patients who have previously documented NTRK or ROS1 gene fusion confirmed by the central laboratory; Phase I dose expansion and Phase II: Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor, patients can provide a written report of pathological diagnosis of NTRK or ROS1 positive tested by qualified laboratory;
- •Phase I dose expansion cohort 1 and Phase II cohort 1: locally advanced, or metastatic solid tumor with NTRK gene fusion Phase I dose expansion cohort 2 and Phase II cohort 2： locally advanced, or metastatic NSCLC with ROS1 gene fusion that has progressed to crizotinib and other therapies or was intolerance to crizotinib Phase I dose expansion cohort 3: locally advanced, or metastatic NSCLC with ROS1 gene fusion who have not previously received crizotinib or other therapy.
- •phase I dose escalation: at least 1 measurable target lesion according to RECIST version 1.1 Phase I dose expansion and Phase II: at least 1 measurable target lesion according to RECIST version 1.1 (Tumor lesions treated with prior radiation or other local treatment are considered measurable if they show definite progression)
- •ECOG PS 0-1
- •Life expectancy ≥ 3 months.
- •Adequate organ function:
- •Baseline laboratory values fulfilling the following requirements: Absolute neutrophils count (ANC) ≥1.5 × 109/L; Platelets (PLTs) ≥75 × 109/L; Hemoglobin ≥ 85g/L; Serum creatinine≤ 1.5 × ULN， or creatinine clearance ≥50 mL/min/1.73m2(only when serum creatinine>1.5 × ULN); Total serum bilirubin ≤1.5 × ULN; Liver transaminases (AST/ALT) ≤ 2.5 × ULN，≤3× ULN if liver metastases are present or liver cancer patients; Activated Partial Thromboplastin Time≤1.5× ULN；International Normalized Ratio (INR)≤1.5× ULN；
- •Eligible patients (male and female) who are fertile must agree to at least use a reliable contraceptive method with partner during the trial and within 90 days from the last dose; Women of childbearing age must have a negative serum pregnancy test within 7 days before the first dose of the trial.
排除标准
- •Received anti-tumor therapy such as chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy or other therapy within 4 weeks prior to the first dose of the investigational drug except the following:
- •Nitroso ureas or mitomycin C within 6 weeks before the first dose of the drug; Oral fluorouracil and small molecule targeted drugs within 2 weeks prior to the first dose of drug or within 5 half life (whichever is longer);
- •Received other unmarketed investigational drugs or treatments within 4 weeks prior to the first dose of the investigational drug;
- •Major organ surgery (except biopsy) or significant trauma within 4 weeks prior to first dose of the investigational drug or required elective surgery during the trial;
- •Adverse reactions to previous antitumor therapy have not recovered to NCI CTCAE 5.0 ≤ grade 1 (except for alopecia, grade 2 peripheral neurotoxicity, stable hypothyroidism after hormone replacement therapy, etc.);
- •Inability to swallow drug, or a condition that the investigator judged to severely affect gastrointestinal absorption (eg:Chronic Diarrhea, intestinal obstruction, etc.);
- •Cerebral or meningeal metastases with clinical symptoms. The below patients were allowed to be included: those who were asymptomatic, stable, and did not require steroid treatment for more than 4 weeks prior to the start of study treatment (if the cerebral metastases had undergone radiotherapy or/and surgery, radiotherapy and surgery should be at least 1 month prior to the first dose) ;
- •Known active infections and currently need intravenous anti-infective therapy;
- •History of immune deficiencies, including positive HIV antibody tests;
- •Active Hepatitis B (HBsAg and/or HBcAb positive with HBV-DNA > 500IU/ml) or hepatitis c virus infection (positive test results of anti-HCV with positive HCV-RNA );
- •Known interstitial lung disease (except for radioactive pulmonary fibrosis that does not require steroid therapy);
- •History of serious cardiovascular disease;
- •Pregnant or lactating women.
研究组 & 干预措施
XZP-5955 tablets
Experimental
XZP-5955 tablets
干预措施: XZP-5955 tablets (Drug)
结局指标
主要结局
Maximum tolerated dose (MTD) (Phase I dose escalation)
时间窗: 24days following first dose of XZP-5955
Determine MTD of XZP-5955
Overall Response Rate (ORR) by Blinded Independent Central Review (BICR) (Phase I dose expansion and phase II)
时间窗: 2 to 3 years after first dose of XZP-5955
Per RECIST v1.1 as assessed by BICR
Number of patients with adverse events (Phase I dose escalation)
时间窗: within 30 days from last dose
Incidence of AE as assessed by CTCAE 5.0
次要结局
- objective response rate (ORR) (Phase I and Phase II)(2 to 3 years after first dose of XZP-5955)
- Progression free survival (PFS) (Phase I and Phase II)(2 to 3 years after first dose of XZP-5955)
- Duration of response (DOR) (Phase I and Phase II)(2 to 3 years after first dose of XZP-5955)
- Disease control rate (DCR) (Phase I and Phase II)(2 to 3 years after first dose of XZP-5955)
- Clinical benefit rate (CBR) (Phase I and Phase II)(2 to 3 years after first dose of XZP-5955)
- Time to response (TTR) (Phase I and Phase II)(2 to 3 years after first dose of XZP-5955)
- Death of response (DpR) (Phase I and Phase II)(2 to 3 years after first dose of XZP-5955)
- Overall survival (OS) (Phase I expansion period and Phase II)(2 to 3 years after first dose of XZP-5955)
- Phase I: Area under the concentration versus time curve of XZP-5955 in plasma (AUC)(Pre-dose, up to 72h after drug on Day 1；pre-dose on day 8, day 15 of cycle 1, , pre-dose and up to 12h after drug on day21 of cycle 1;pre-dose on day1 of cycle 2 and 3)
- Phase I: Maximum plasma concentration (Cmax) of XZP-5955(Up to 72 hours post dose of Day 1)
- Phase I: Oral clearance (CL/F) of XZP-5955(Pre-dose, up to 72h after drug on Day 1；pre-dose on day 8, day 15 of cycle 1, pre-dose and up to 12h after drug on day21 of cycle 1;pre-dose on day1 of cycle 2 and 3)
- Intracranial objective response rate (Phase I expansion period and Phase II)(To determine the intracranial ORR)
- Number of patients with adverse events ((Phase I dose expansion and Phase II)(within 30 days from last dose)
- Pop PK of XZP-5955 and its metabolite (Phase II)(pre-dose, Tmax on Day1, pre-dose on day 8 of cycle 1, pre-dose on day 1 of Cycle 2, Tmax,ss on Day 1 of cycle 2, pre-dose on day 1 of cycle 3)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy VolunteersInflammationNCT01570205Xigen SA24
已完成
1 期
A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid TumorsSolid TumorNCT06209385Shanghai Haiyan Pharmaceutical Technology Co., Ltd.14
已完成
1 期
A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548PainNCT05851157Vertex Pharmaceuticals Incorporated73
已完成
1 期
A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular DegenerationNeovascular Age-Related Macular DegenerationNCT03387566Huabo Biopharm Co., Ltd.21
已完成
1 期
A Study of Injection HB002.1T in Subjects With Solid TumorSolid TumorNCT03636750Huabo Biopharm Co., Ltd.27